Syndromic microphthalmia type 5

Syndromic microphthalmia type 5 (also known as microphthalmia syndromic type 5 or MCOPS5) is an extremely rare genetic disorder characterized by microphthalmia (abnormally small eyes) or anophthalmia (absence of one or both eyes) occurring alongside additional systemic abnormalities. This condition is caused by mutations in the OTX2 gene, which encodes a transcription factor critical for early eye and brain development. The OTX2 gene plays a fundamental role in the formation of the anterior structures of the brain, the retina, and the pituitary gland during embryonic development. The clinical features of syndromic microphthalmia type 5 extend beyond the eyes and can affect multiple organ systems. Key ocular findings include bilateral or unilateral microphthalmia or anophthalmia, often accompanied by other eye anomalies such as retinal dystrophy or optic nerve hypoplasia. Importantly, many affected individuals also present with pituitary abnormalities leading to hypopituitarism, which can manifest as growth hormone deficiency, hypogonadotropic hypogonadism, or other endocrine deficiencies. Developmental delay and intellectual disability of variable severity may also be present. Brain malformations, including structural anomalies of the cerebral cortex and posterior fossa, have been reported in some patients. There is currently no cure for syndromic microphthalmia type 5. Management is supportive and multidisciplinary, involving ophthalmologists for prosthetic eye fitting and visual rehabilitation when possible, endocrinologists for hormone replacement therapy in cases of pituitary insufficiency, and developmental specialists for neurocognitive support. Early identification of pituitary hormone deficiencies is particularly important, as untreated hormonal deficits can lead to significant morbidity. Genetic counseling is recommended for affected families.

Common questions about Syndromic microphthalmia type 5